Subscribe

Find a Job | Employers

Biogen Idec

Through cutting-edge science and medicine, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies for neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, we are the world's oldest independent biotechnology company, and as an organization, we are focused on meeting the needs of our patients, developing therapies to help improve quality of life and providing innovative methods for long-term treatment.

To our patients, we are the trusted source of vital therapies for multiple sclerosis, such as TECFIDERA® (dimethyl fumarate), AVONEX® (interferon beta-1a), TYSABRI® (natalizumab) and FAMPYRA® (prolonged-release fampridine tablets). We also discovered and co-market RITUXAN®, the world's most prescribed treatment for non-Hodgkin's lymphoma and an effective treatment for rheumatoid arthritis. Medications such as these, along with the many different support programs we offer, help our patients deal with the rigors of living with serious illness.

To our employees, we are an exciting and invigorating place to work, an ambitious company where courageous innovation is encouraged and expected – not just of scientists, but of every employee. This is exemplified in every aspect of our business – from our Pharmaceutical Operations and Technology group, who deliver world-class expertise and capabilities in protein engineering and biologics manufacturing, to our customer service representatives, who support our patient communities by offering straightforward information, assistance and patient services. Across the company – in marketing, sales, quality control and human resources – people are empowered to challenge conventional wisdom and propose better ways of doing things.

And to our neighbors, we are committed to responsible corporate citizenship, incorporating our efforts directly into our culture and our business activities. We strive to create economic, social and environmental value for our company and our stakeholders with robust programs focused on philanthropy and community engagement, as well as by addressing critical issues like diversity and sustainability.

As a Fortune 500 company, we have plans for substantial future growth by focusing our resources on the areas where we have the most expertise and most promising assets. This year and beyond, we intend to:

  • Pursue first-in-class and best-in-class products through a combination of internal research and development and strategic partnerships;
  • Innovate at the intersection of science, medicine and economics to transform the drug development process;
  • Advance a robust pipeline of candidates, targeting exciting new areas of high unmet medical need;
  • Transform the standard of care in hemophilia through the treatment of hemophilia A and B with our long-lasting recombinant proteins for factors VIII and IX; and
  • Expand our global footprint, bringing our therapies to patients that need them around the world, and to work with partners to drive future innovation.

At Biogen Idec, we are proud of our 35 years of contributions to the biotechnology industry, and we look forward to continuing to shape the future of an industry that transforms scientific discovery into advances in patient care. To learn how you can join us in this important mission, visit www.biogenidec.com/careers and explore our current opportunities.